{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:55Z","timestamp":1791219235143,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00262-017-2062-3","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T13:52:00Z","timestamp":1505397120000},"page":"61-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report"],"prefix":"10.1007","volume":"67","author":[{"given":"Jumpei","family":"Kashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Shimizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"issue":"14","key":"2062_CR1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.2015.63.8049","volume":"34","author":"B Melosky","year":"2016","unstructured":"Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V (2016) Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol 34(14):1676\u20131688","journal-title":"J Clin Oncol"},{"issue":"2","key":"2062_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"17","key":"2062_CR3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"5","key":"2062_CR4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00534-012-0521-y","volume":"19","author":"H Ohara","year":"2012","unstructured":"Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, Tazuma S, Uchida K, Hirano K, Yoshida H, Nishino T (2012) Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 19(5):536\u2013542","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2062_CR5","unstructured":"U.S.FDA. Administration (2014) OPDIVO (nivolumab) Injection label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125554lbl.pdf . Accessed 8 Apr 2017"},{"key":"2062_CR6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","volume":"99","author":"K Ikeuchi","year":"2016","unstructured":"Ikeuchi K, Okuma Y, Tabata T (2016) Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer 99:148\u2013150","journal-title":"Lung Cancer"},{"issue":"4","key":"2062_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574","journal-title":"Ann Oncol"},{"key":"2062_CR8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo K, Sato T, Kudo M, Ito A, Nakagawa K (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536","journal-title":"Invest New Drugs"},{"issue":"3","key":"2062_CR9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28(3):671\u2013672","journal-title":"Ann Oncol"},{"issue":"19","key":"2062_CR10","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM (2010) Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175","journal-title":"J Clin Oncol"},{"key":"2062_CR11","unstructured":"U.S.FDA. Administration (2014) KEYTRUDA (pembrolizumab) Injection label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125514lbl.pdf . Accessed 8 Apr 2017"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2062-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T17:25:44Z","timestamp":1602955544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2062-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2062-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}